![](https://i0.wp.com/saarum.co.in/wp-content/uploads/2015/06/oncoprime-brca-logo-e1444648188685.png?fit=480%2C73)
Use a primary cell-based platform that truly represents the clinical diversity of breast cancer – Switch to OncoPrime – Breast Cancer
![](https://i0.wp.com/saarum.co.in/wp-content/uploads/2015/06/oncoprime-brca-img2.png?fit=633%2C383)
Based on biomarker expression breast cancer can be categorized into four major subtypes. Triple negative (TNBC) tumors respond best to chemotherapy similar to other aggressive cancers. Luminal A tumors respond best to endocrine therapy e.g. antiestrogen or aromatase inhibitor
![](https://i0.wp.com/saarum.co.in/wp-content/uploads/2015/06/oncoprime-brca-img1.png?fit=608%2C296)
Diversity of samples available in the biobank. With steady inflow of patient
samples, we have banked a generous diversity of Breast cancer samples. The chart represents high level categories only. Breast cancer staging as per WHO guidelines.
samples, we have banked a generous diversity of Breast cancer samples. The chart represents high level categories only. Breast cancer staging as per WHO guidelines.
![](https://i1.wp.com/saarum.co.in/wp-content/uploads/2015/06/Breast-Cancer-Panel.jpg?fit=757%2C414)